was generally regarded as a disease of keratinocytes; the inflammatory response was thought to be secondary. Later, psoriasis came to be considered an autoimmune disease in which T lymphocytes play central roles. T cells are almost certainly involved in the initiation of psoriatic lesions. Activated T cells of the dermal-epidermal junction are thought to drive the hyperplastic proliferative response by elaborating T helper cell 1 cytokines, including tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and various ILs 4 . The purpose of the present study was to examine the effect of low-dose CsA on the immune systems of Korean patients with psoriasis, by counting the numbers of T, B, and NK cells. higher in the patients treated for more than 1 year, but the difference was not significant (Fig. 1B) . After the efficacy of CsA in treating psoriasis was first reported in 1979, subsequent studies showed that low doses of the drug yielded acceptable results even in patients with severe recalcitrant psoriasis 5 . CsA is the first immunosuppressive drug to directly target T cells. Helper T cells are the principal targets, but T-suppressor cells may also be affected. CsA forms a complex with cyclophilin; the complex inhibits calcineurin phosphatase. Consequently, the enzyme is unable to phosphorylate "nuclear factor of activated T cells," which thus cannot enter the nucleus to promote transcription of genes encoding cytokines such as interleukin (IL)-2, IFN-γ, granulocyte macrophage colony stimulating factor (GM-CSF), IL-3, IL-4, TNF-α 6 . As a result, CsA depletes lymphocyte and macrophage numbers in the epidermis and dermis, and inhibits activation of T, B, and NK cells [1] [2] [3] .
Conflicting reports on the effects of low-dose CsA on T cells have appeared. Brandt et al. 7 found that low-dose , and CD8 + cell numbers remained unchanged significantly. Also, the mean post-treatment PASI decreased significantly after CsA treatment. Thus, we suggest that partial inhibition of T-cell activity may be adequate to improve the PASI, and systemic suppression in T-cell activity may not necessarily accompany the beneficial effect that is seen with CsA in psoriasis. 
